SOURCE: Barrier Therapeutics, Inc.

April 26, 2005 10:00 ET

Barrier Therapeutics to Release First Quarter 2005 Financial Results on May 3, 2005

Company Also Announces Presentation at Morgan Stanley Annual Global Healthcare Unplugged Conference

PRINCETON, NJ -- (MARKET WIRE) -- April 26, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the first quarter of 2005, on Tuesday, May 3, 2005, and will sponsor a conference call at 5:00 p.m. eastern time to provide a company update and discuss the financial results for the quarter. Interested investors can listen to the call live over the Internet in the investor relations section of the Company's website located at or by dialing 1-800-322-0079 (U.S.) or 1-973-409-9258 (International).

The Company will also present at the Morgan Stanley Annual Global Healthcare Unplugged Conference on Thursday, May 5th at 3:45 p.m. eastern time. Dr. Geert Cauwenbergh, Chairman and Chief Executive Officer of Barrier Therapeutics, will provide an update to the investment community on Barrier's marketed product, Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution, and its clinical-stage product pipeline. The conference is being held from May 4-6, 2005, at the Mandarin Oriental Hotel in Miami, Florida. Dr. Cauwenbergh's presentation will also be available live via a webcast that can be accessed through the Company's website:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® for the treatment of solar lentigines in the U.S., a common condition also known as "age spots" or "liver spots," and for the broader indication including related hyperpigmented lesions in Canada. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is in registration and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, fungal infections, including vaginal candidiasis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Contact Information

  • Contacts:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Emily Poe